Holen Sie sich die Stockscreener-App
43.79
9.47%
3.79
Schlusskurs vom Vortag:
$40.00
Offen:
$39.84
24-Stunden-Volumen:
12.63M
Relative Volume:
2.80
Marktkapitalisierung:
$26.93B
Einnahmen:
$3.91B
Nettoeinkommen (Verlust:
$823.88M
KGV:
33.02
EPS:
1.3262
Netto-Cashflow:
$875.28M
1W Leistung:
+18.35%
1M Leistung:
+26.01%
6M Leistung:
+62.31%
1J Leistung:
+46.60%
1-Tages-Spanne:
$39.63
$44.34
1-Wochen-Bereich:
$37.76
$44.34
52-Wochen-Spanne:
$23.62
$44.34
Genmab Adr Stock (GMAB) Company Profile
Compare GMAB vs VRTX, REGN, MRNA, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GMAB
Genmab Adr
|
43.79 | 26.93B | 3.91B | 823.88M | 875.28M | 1.3262 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-07-22 | Hochstufung | TD Cowen | Hold → Buy |
| 2026-05-27 | Eingeleitet | Truist | Buy |
| 2026-04-22 | Hochstufung | Goldman | Neutral → Buy |
| 2026-03-27 | Eingeleitet | Wolfe Research | Outperform |
| 2026-03-02 | Eingeleitet | Wells Fargo | Overweight |
| 2026-02-17 | Fortgesetzt | Jefferies | Buy |
| 2026-02-17 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-04-01 | Herabstufung | Bernstein | Mkt Perform → Underperform |
| 2025-03-11 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-02-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-08 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-09-04 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-08-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-02-23 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2024-01-22 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-12-06 | Hochstufung | UBS | Neutral → Buy |
| 2023-11-10 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-11-08 | Hochstufung | DNB Markets | Sell → Buy |
| 2023-10-18 | Eingeleitet | Exane BNP Paribas | Underperform |
| 2023-09-06 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-24 | Eingeleitet | BTIG Research | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-31 | Eingeleitet | UBS | Neutral |
| 2023-05-12 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-12-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-11-14 | Eingeleitet | William Blair | Mkt Perform |
| 2022-11-11 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-05-02 | Eingeleitet | Cowen | Market Perform |
| 2022-03-16 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-31 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-12-01 | Eingeleitet | Berenberg | Sell |
| 2021-09-16 | Herabstufung | Jefferies | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-08-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-20 | Eingeleitet | Deutsche Bank | Buy |
| 2021-01-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-09-23 | Herabstufung | Bryan Garnier | Neutral → Sell |
| 2020-09-08 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-06-25 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-04-23 | Eingeleitet | Credit Suisse | Outperform |
| 2020-02-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-12-12 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-09-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-09-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-08-12 | Eingeleitet | Guggenheim | Buy |
| 2019-08-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-08-12 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Genmab Adr Aktie (GMAB) Neueste Nachrichten
Genmab reports USD 4.24 billion DARZALEX sales and BofA targets Genmab stock at DKK 2,850 - ad-hoc-news.de
Genmab A/S (GMAB.CO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Genmab A/S (GMAB) Stock Price, News, Quote & History - Yahoo! Finance Canada
Genmab A/S ADS (GMAB) Ticks Up 0.81% as Shares Hold Above $37Exhaustion Gap - www.dars.gov.et
Genmab stock gains as capital increase and updated Articles of Association support growth plans - AD HOC NEWS
Genmab A/S ADS (GMAB) Slips 1.64% as Shares Test Key Support ZoneMutual Fund Flow - https://www.siam.in/
Genmab A/S ADS (GMAB) Slips 1.64% as Shares Test Key Support ZoneBlock Trade Flow - https://www.dars.gov.et/
Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members - The Manila Times
Genmab A/S Stock 12‑Month Price Target Raised to $42, Implies 9% Upside - TradingView
AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL - Zacks Investment Research
Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength? - Zacks Investment Research
Stock Market Today, Oct. 5: Tech Momentum Lifts Nasdaq as Treasury Yields Surge - The Motley Fool
Genmab stock gains 5.32 percent on Rina-S data - AD HOC NEWS
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma - GlobeNewswire Inc.
Genmab stock after-hours at EUR 319.90: minus 0.03 percent versus the prior close at Lang & Schwarz - AD HOC NEWS
Genmab reports Rina-S results. Genmab stock falls 1.95 percent - AD HOC NEWS
Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer - GlobeNewswire Inc.
Major Shareholder Announcement - GlobeNewswire Inc.
Genmab A/S Stock 12‑Month Price Target Raised to $39.56, Implies 14% Upside - TradingView
HC Wainwright keeps Buy on Genmab stock at USD 40 target - AD HOC NEWS
GMAB Q2 2026 Earnings: EPS Beats Consensus by 36.6% as Shares Edge HigherEarnings Surprise Report - https://www.dars.gov.et/
Genmab stock last trades at DKK 2,282.00 on September 28, 2026 - AD HOC NEWS
Genmab stock at DKK 2,277 on September 25, 2026, up 0.40 percent - AD HOC NEWS
Genmab stock gains 0.8 percent ahead of the open - AD HOC NEWS
Grant of Restricted Stock Units and Warrants to Employees in Genmab - GlobeNewswire Inc.
Genmab stock heads into the open after a 0.84 percent gain - AD HOC NEWS
Genmab stock gains as Kempen raises target to DKK 3,300 - AD HOC NEWS
Genmab stock heads into the open after a 10.80 percent year gain - AD HOC NEWS
Genmab stock advances as Q4 readouts stay on track - AD HOC NEWS
GMAB Q2 2026 Earnings: EPS Beats Consensus by 36.6% as Shares Edge HigherEarnings Analysis - www.dars.gov.et
GMAB Q2 2026 Earnings: EPS Beats Consensus by 36.6% as Shares Edge HigherEarnings Cycle Outlook - dars.gov.et
Genmab stock holds steady after first-half 2026 earnings update - AD HOC NEWS
Genmab stock gains as petosemtamab and Q2 figures draw focus - AD HOC NEWS
Genmab stock gains as petosemtamab Phase 3 start and strong Q2 figures support valuation - AD HOC NEWS
Genmab stock heads into the open after a modest gain - AD HOC NEWS
Genmab stock gains as HC Wainwright lifts Q3 earnings estimates and Phase 3 petosemtamab trial begin - AD HOC NEWS
Genmab stock gains as HC Wainwright lifts earnings estimates and confirms Buy rating - AD HOC NEWS
Genmab stock heads into the open after a 1.6% gain in Copenhagen - AD HOC NEWS
Coloplast stock edges lower despite strong quarterly profit surge - AD HOC NEWS
Genmab stock gains as capital increase and updated Articles of Association support growth plans - AD HOC NEWS
Genmab stock gains support as Barclays lifts target after warrant-driven share issue - AD HOC NEWS
Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 – SNS Insider - GlobeNewswire Inc.
symbol__ Stock Quote Price and Forecast - CNN
Capital Increase in Genmab as a Result of Employee Warrant Exercise - GlobeNewswire Inc.
Notice to Convene an Extraordinary General Meeting of Genmab A/S - The Manila Times
Notice to Convene an Extraordinary General Meeting of Genmab A/S - Yahoo Finance UK
ETFs Investing in Genmab A/S Sponsored ADR Stocks - TradingView
Genmab stock holds steady as analysts stick to a moderate buy view - AD HOC NEWS
Genmab A/S ADSADR Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Genmab (GMAB) Q2 2026 Earnings: EPS Surges 36.6% Past EstimatesCost Structure Review - careplusvn.com
Finanzdaten der Genmab Adr-Aktie (GMAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Genmab Adr-Aktie (GMAB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GENMAB A/S | 10% Owner |
Dec 26 '25 |
Buy |
97.00 |
2,978 |
288,866 |
72,831,487 |
| GENMAB A/S | 10% Owner |
Dec 26 '25 |
Buy |
97.00 |
142,610 |
13,833,170 |
72,828,509 |
| GENMAB A/S | 10% Owner |
Dec 24 '25 |
Buy |
97.00 |
96,082 |
9,319,954 |
72,685,899 |
| GENMAB A/S | 10% Owner |
Dec 23 '25 |
Buy |
97.00 |
561,042 |
54,421,074 |
72,589,817 |
| GENMAB A/S | 10% Owner |
Dec 22 '25 |
Buy |
97.00 |
15,710 |
1,523,870 |
72,028,775 |
| GENMAB A/S | 10% Owner |
Dec 19 '25 |
Buy |
97.00 |
66,264 |
6,427,608 |
72,013,065 |
| GENMAB A/S | 10% Owner |
Dec 18 '25 |
Buy |
97.00 |
212,177 |
20,581,169 |
71,946,801 |
| GENMAB A/S | 10% Owner |
Dec 17 '25 |
Buy |
97.00 |
150,795 |
14,627,115 |
71,734,624 |
| GENMAB A/S | 10% Owner |
Dec 16 '25 |
Buy |
97.00 |
120,752 |
11,712,944 |
71,583,829 |
2.56%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):